UK

Isomorphic Labs Secures $5Bn in Series C Funding to Develop AI-Powered Medicines

Nov 18, 2026 | By Oliver Bennett

Isomorphic Labs Secures $5Bn in Series C Funding to Develop AI-Powered Medicines

Isomorphic Labs, an AI company focused on discovering and developing new medicines, has raised €4.5 billion ($5 billion) in a Series C funding round. The company will use the investment to speed up its research and develop more advanced AI technology for drug discovery.

SUMMARY

  • Isomorphic Labs has raised €4.5 billion ($5 billion) in a Series C funding round.
  • The round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and Alphabet.
  • Founded in 2021, Isomorphic Labs develops AI technology for drug discovery and medicine development.

The funding round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz. Alphabet also made a significant investment in the round, continuing its support for the company.

All of Isomorphic Labs' existing investors also participated in the funding round. These include Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,” says Sir Demis Hassabis, founder and CEO of Isomorphic Labs. “Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”

“Isomorphic Labs is building foundational technology for the future of medicine,” adds Konstantine Buhler, Partner at Sequoia Capital. “It’s inspiring to see the Isomorphic team translate advanced AI into a growing portfolio of drug candidates. Using AI to improve human health is one of the most important challenges of our generation. We’re proud to co-lead this round and help further scientific discovery in medicine.”

“Every week we are making repeatable scientific advancements enabled by our models,” says Max Jaderberg, President of Isomorphic Labs. “These translate directly into better molecular profiles with the potential to be new medicines and unlock some of the hardest problems in drug discovery. Our interdisciplinary teams combine world-leading machine learning researchers with top-class drug hunters and together they are routinely solving complex biological problems that have stalled traditional research for decades.

Isomorphic Labs was founded in 2021. The company has developed an advanced AI platform for drug discovery. Its AI models can be used to research different diseases and develop various types of medicines.

Isomorphic Labs: “Solve all disease” headline, three cards on IsoDDE, AlphaFold and the company name, quotes from Demis Hassabis and Max Jaderberg, and contact details.

The company is now expanding its AI drug design platform, called IsoDDE, and building a pipeline of potential medicines developed using AI.

IsoDDE brings together several advanced AI models that can simulate and study how medicines work. The platform is designed to support drug development across different treatment areas and types of medicines.

Read Also- Nomadic Secures $6Mn to Develop Autonomous Power Line Monitoring Drones

Recommended Stories for You